Impact of First SARS‐CoV‐2 Infection Variant on Serological Responses Against Omicron: Findings From the SIREN Study
Influenza and Other Respiratory Viruses · 2026
DOI: 10.1111/irv.70204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2026. Verfasst von Ferdinando Insalata und 12 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial Resistance and Healthcare Associated Infections Division, United Kingdom Health Security Agency (UKHSA), London, UK. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, Reinfection. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKHSA, Medical Research Council, Francis Crick Institute.
Abstract (Originalsprache)
Introduction
Despite the existing hybrid immunity, a sharp increase in SARS‐CoV‐2 reinfections was observed worldwide following Omicron variant emergence. We investigated whether the first infecting variant indelibly shapes serological responses against Omicron (BA.1 and BA.2) reinfection.
Methods
Participants with a sequence‐confirmed Alpha ( n = 23) or Delta ( n = 10) first infection before third vaccine dose (V3) that subsequently had a BA.1 or BA.2 reinfection were selected. Sera were tested for anti‐SARS‐CoV‐2 spike (anti‐S) and live virus microneutralisation (LV‐N) against Ancestral, Alpha, Delta, Omicron BA.1 and BA.2. Antibody responses and waning post‐V3 were compared by first infection variant using mixed‐effect models, as well as inferred titres days before reinfections. Individual's neutralisation responses were compared 12 weeks post‐V3, among those with Alpha and Delta primary infection.
Results
After V3, those with Delta first infection had higher LV‐N Omicron BA.1 titres (fold difference (FD) = 2.7, p = 0.05) compared to Alpha primary infection. Participants with Delta first infection presented higher LV‐N BA.1 (FD = 1.89, p = 0.004) and LV‐N BA.2 (FD = 2.06, p = 0.001) titres pre‐Omicron reinfections. Individuals' neutralisation responses against Ancestral were higher than any other subsequent variants, regardless of first infection variant.
Conclusions
A previous Delta SARS‐CoV‐2 infection induced a higher serological response against a subsequent Omicron infection when compared to Alpha first infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Antimicrobial Resistance and Healthcare Associated Infections Division, United Kingdom Health Security Agency (UKHSA), London, UK.
- Department of Mathematics, Imperial College London, London, UK.
- UCL Centre for Kidney & Bladder Health, Royal Free Hospital, London, UK.
- The Francis Crick Institute, London, UK.
- Emerging Pathogen Serology, UK Health Security Agency (UKHSA), Salisbury, UK.
- COVID Surveillance Unit, The Francis Crick Institute, London, UK.
ORCID-Profile: Ana Atti
Förderung
- UKHSA
- Medical Research Council
- Francis Crick Institute
- Wellcome Trust
- Cancer Research UK
Zitieren
APA
Insalata, F., Atti, A., Carr, E. J., Otter, A. D., SIREN study group, Foulkes, S., Dowgier, G., Hobbs, A., Wu, M. Y., Hopkins, S., Charlett, A., Beale, R., & Hall, V. (2026). Impact of First SARS‐CoV‐2 Infection Variant on Serological Responses Against Omicron: Findings From the SIREN Study. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70204
Vancouver
Insalata F, Atti A, Carr EJ, Otter AD, SIREN study group, Foulkes S, et al. Impact of First SARS‐CoV‐2 Infection Variant on Serological Responses Against Omicron: Findings From the SIREN Study. Influenza and Other Respiratory Viruses. 2026. doi:10.1111/irv.70204
BibTeX
@article{Insalata2026,
author = {Insalata, Ferdinando and Atti, Ana and Carr, Edward J and Otter, Ashley D and SIREN study group, SIREN study group and Foulkes, Sarah and Dowgier, Giulia and Hobbs, Agnieszka and Wu, Mary Y and Hopkins, Susan and Charlett, Andre and Beale, Rupert and Hall, Victoria},
title = {Impact of First SARS‐CoV‐2 Infection Variant on Serological Responses Against Omicron: Findings From the SIREN Study},
journal = {Influenza and Other Respiratory Viruses},
year = {2026},
doi = {10.1111/irv.70204}
}
EUVIMED